PubMed Health⌕ Search

Biomedical subjects

P Dick

Publications and source records attributed to P Dick.

At least 19 recordsLinked to original sources
PubMed2005

Haem oxygenase-1 genotype and cardiovascular adverse events in patients with peripheral artery disease.

BACKGROUND: A functional GT dinucleotide length polymorphism in the haem oxygenase-1 (HO-1) gene promoter is thought to be involved in the pathogenesis of cardiovascular disease. Short (< 25) (GT)n repeats are suggested to facilitate enhanced HO-1 up-regulation in response to injury and confer potent anti-inflammatory and antioxidative effects. MATERIALS AND METHODS: We investigated the association between the HO-1 GT-polymorphism and cardiovascular outcome in 472 patients with advanced peripheral artery disease. Cardiovascular risk profile and DNA samples for determination of the HO-1 genotype (carrier vs. noncarrier of a short (GT)n repeat allele) were obtained at baseline, and patients were followed for median 21 months for the occurrence of coronary events (myocardial infarction, percutaneous coronary interventions and coronary artery bypass graft), cerebrovascular events (stroke or carotid revascularization) and all-cause mortality. RESULTS: Coronary events occurred in 48 patients (9%), cerebrovascular events in 40 patients (9%) and 59 patients (13%) died. In total, 173 major adverse cardiovascular events (MACE) occurred in 133 patients (28%). Carriers of the short (GT)n repeat allele had a 0.46-fold reduced adjusted hazard ratio for coronary events (P = 0.016) as compared to noncarriers. No significant difference was found for cerebrovascular events, mortality and overall MACE. CONCLUSION: Apparently, the HO-1 genotype exerts potentially protective effects against coronary adverse events in patients with peripheral artery disease. Homozygous and heterozygous carriers of < 25 (GT)n repeats had lower rates of myocardial infarction, percutaneous coronary interventions and coronary bypass operations compared to patients with longer (GT)n repeats.

Aged↗
PubMed2005

Effects of monensin and stage of lactation on variation of blood metabolites within twenty-four hours in dairy cows.

Effects of prepartum administration of a monensin controlled release capsule (CRC) and stage of lactation on variation of blood metabolites within 24 h were determined in 16 dairy cows. Cows were fed a total mixed ration ad libitum twice daily at 0700 and 1300 h. At calving, cows were switched from a close-up dry cow diet to a lactating cow diet. Cows were blood sampled every 3 h for 24 h at 3 stages of lactation, including 1 wk before calving (wk -1), 1 wk after calving (wk 1), and 6 wk after calving (wk 6). Serum concentrations of glucose, beta-hydroxybutyrate (BHBA), nonesterified fatty acids (NEFA), and urea exhibited significant variation within 24 h. Glucose and NEFA were, respectively, 0.09 and 0.08 mM lower between 1030 and 2230 h than between 2230 and 1030 h. beta-Hydroxybutyrate and urea were, respectively, 95.1 and 0.49 mM higher between 1030 and 2230 h than between 2230 and 1030 h. Monensin did not significantly affect glucose, NEFA, and urea in this study. Monensin reduced BHBA at wk 1, but not at wk -1 or wk 6. Glucose was lower and BHBA and NEFA were higher at wk 1 compared with wk -1 and wk 6. Urea was higher at wk 6 compared with wk -1. The variation within 24 h of glucose, BHBA, and NEFA were not affected by monensin and stage of lactation. Diurnal variation of urea was affected by stage of lactation, but not by monensin.

3-Hydroxybutyric Acid↗
PubMed2004

Infant hospitalization and maternal depression, poverty and single parenthood - a population-based study.

OBJECTIVES: There is variation in rates of hospitalization for young children which is unexplained by differences in health. We used population-based survey data to examine the contribution of family sociodemographic and psychodynamic factors to the risk of hospitalization in children under the age of 2 years in Canada. METHODS: Baseline data from the National Longitudinal Survey of Children and Youth (a population-based study of child health and well-being) were used. A weighted sample of 332 697 (unweighted n = 2184) children between the age of 12 and 24 months, whose biological mother reported data on hospitalization over the past year, were included. Logistic regression analyses were conducted to estimate the risk of hospitalization by sociodemographic and psychodynamic factors controlling for important biological covariates. RESULTS: The overall proportion of children who were hospitalized was 11.2%. After adjusting for prematurity, the only statistically significant biological factor associated with the risk of hospitalization was reported present health [odds ratio (OR) 4.04, 95% confidence intervals (CI): 2.93, 5.58]. However, three family variables were significantly associated with hospitalization: low income adequacy (OR 1.66, 95% CI: 1.15, 2.40), single parenthood (OR 1.55, 95% CI: 1.03, 2.34) and maternal depression (OR 1.81, 95% CI: 1.22, 2.69). Having a parent who is a recent immigrant to Canada is associated with a reduced risk of hospitalization (OR 0.53, 95% CI: 0.35, 0.78). CONCLUSIONS: Most of the significant associations with hospitalization in the first 2 years of life in the Canadian population relate to the overall family's social and mental health. Maternal depression is a treatable disorder which if recognized might prevent some infant morbidity.

Child, Preschool↗
PubMed2004

Comparison of techniques for measurement of rumen pH in lactating dairy cows.

Subacute rumen acidosis is thought to be a common condition in early lactating dairy cattle; however, diagnosis is difficult. There are currently only two techniques available for measuring rumen pH under field conditions: rumenocentesis and oral stomach tube. Sixteen rumen-fistulated cows were sampled in four sites of the rumen (cranial-ventral, caudal-ventral, central, and cranial-dorsal) with a rumen cannula. Rumen pH results were compared to those obtained at the same time with rumenocentesis and with an oro-ruminal (Geishauser) probe. Rumen fluid was obtained between 6 and 12 wk of lactation. Samples were analyzed for pH, lactate, bicarbonate, sodium, potassium, and chloride. Rumen pH results were also compared to those obtained from 24-h continuous rumen pH measurement using indwelling rumen pH probes. Oro-ruminal probe samples had the highest pH values and the highest bicarbonate concentrations. Rumenocentesis samples had the lowest pH values and the lowest bicarbonate concentrations. Small differences in electrolyte concentrations were noted among rumen fluid collection techniques in the different rumen sites. The highest correlations of rumen pH were obtained between rumenocentesis and rumen cannulation (cranial-ventral), and between rumen cannulation (cranial-ventral) and the 24-h indwelling pH meter. Compared with samples obtained from the cranial-ventral rumen, rumenocentesis was more sensitive than the oro-ruminal probe in the measurement of low rumen pH; both techniques were moderately specific. The most accurate field technique was rumenocentesis. Improved field techniques are required for better on-farm diagnosis of subacute rumen acidosis.

Acidosis↗
PubMed2004

Effects of monensin on ruminal forage degradability and total tract diet digestibility in lactating dairy cows during grain-induced subacute ruminal acidosis.

The effects of monensin premix supplementation on ruminal pH characteristics and forage degradability, and total tract diet digestibility during grain-induced subacute ruminal acidosis (SARA) in lactating dairy cows receiving a total mixed ration were investigated. Six multiparous, rumen-fistulated Holstein cows were used in a 2-treatment, 2-period (5 wk per period) crossover design. During wk 5 (d 29 to 35) of each period, SARA was induced using a grain challenge model, and ruminal pH was measured continuously using indwelling pH probes. Ruminal degradation of corn silage and alfalfa haylage was determined using the in situ (nylon bag) technique, and total tract diet digestibility was determined by total fecal collection during wk 5. Monensin supplementation did not affect dry matter intake, milk yield, and composition, and ruminal pH characteristics under these experimentally induced SARA conditions. Rates of ruminal forage fiber degradability were similar between control and monensin-treated cows; however, monensin supplementation increased total tract fiber digestion. This study indicates that monensin altered total tract nutrient digestion by increasing fiber digestion at postruminal sites.

Acidosis↗
PubMed2003

Efficacy of intramammary tilmicosin and risk factors for cure of Staphylococcus aureus infection in the dry period.

The objective ofthis study was to evaluate the efficacy of intramammary tilmicosin, administered at drying-off, for eliminating Staphylococcus aureus infection, and to identify risk factors for S. aureus cure during the dry period. A total of 219 naturally infected cows, representing 308 quarters, were randomized to receive either one of two treatments at drying-off. Cows received either an intramammary infusion of 500 mg of benzathine cloxacillin, or a sterile solution containing 1,500 mg of tilmicosin. All cows had quarter milk samples taken aseptically three times before dry-off, and at wk 1, 2, and 4 of the subsequent lactation. Overall, 62% of cows and 67.5% of quarters infected with S. aureus cured during the dry period. The cure following administraton of tilmicosin was 67.3 and 72.5% for cows and quarters, respectively. By comparison, the cure achieved with cloxacillin was 56.9 and 62.9% of cows and quarters. Cows receiving tilmicosin were 2.1 times more likely to cure. The cure rate for cows decreased as the linear score on the last DHI test increased, and as the amount of S. aureus being shed increased. Quarters that cultured positive multiple times before drying-off were less likely to cure. Staphylococcus aureus infections located in front quarters of the udder were 2 times more likely to cure than those in hind quarters. Results of this study demonstrate that intramammary tilmicosin at drying-off is efficacious in curing existing S. aureus during the dry period. Risk factors associated with the cure of S. aureus were identified.

Animals↗
PubMed2003

Effect of a monensin controlled release capsule on metabolic parameters in transition dairy cows.

A prospective field study involving 251 Holstein cows and heifers from five dairy farms near Guelph, Ontario, Canada, was conducted to measure the effect of monensin delivered in a controlled release capsule 3 wk precalving on metabolic function in dairy cows immediately pre- and postcalving. At 3 wk before expected calving, cows were randomly assigned to receive either a controlled release capsule containing monensin or to serve as negative controls. Cows were blood sampled once per week precalving and once in the week following calving, at the same time of day and the same day of the week. Serum was evaluated for beta-hydroxybutyrate (BHBA), nonesterified fatty acids (NEFA), cholesterol, urea, glucose, calcium, and phosphorus. Monensin-treated cows had significantly decreased NEFA and BHBA and significantly increased concentrations of serum cholesterol and urea in the week immediately precalving. No effect of treatment was observed for calcium, phosphorus, or glucose in the precalving period. After calving, concentrations of phosphorus were lower and BHBA tended to be lower, and cholesterol and urea were higher in monensin-treated cows. There was no effect of treatment on NEFA, glucose, or calcium in the first week postcalving. Monensin treatment administered precalving significantly improved indicators of energy balance in both the immediate precalving and postcalving periods. The findings indicate better energy metabolism in monensin-treated cows as they approach calving. Improvement of energy balance before calving is important for the prevention of energy associated metabolic diseases, such as retained placenta, clinical ketosis, and displaced abomasum, which might occur immediately postcalving.

3-Hydroxybutyric Acid↗
PubMed2003

Ovarian follicular activity in lactating Holstein cows supplemented with monensin.

The objective of this study was to determine effects of monensin on ovarian follicular development and reproductive performance in postpartum dairy cows. Forty-eight multiparous Holstein cows were randomly assigned to receive either a control total mixed ration (n = 24) or the same diet plus 22 mg of monensin/kg (n = 24) from 21 d before anticipated calving until cows were either confirmed pregnant or were >180 d postpartum. Monensin had no effect on development of the first dominant follicle postpartum or the numbers of class 1 (3 to 5 mm), 2 (6 to 9 mm), or 3 (10 to 15 mm) follicles. Control cows had more class 4 (>15 mm) follicles at 10 to 13 d postpartum than cows in the monensin group. The first dominant follicle postpartum ovulated, regressed, or became cystic unrelated to differences between diets. However, the first ovulation postpartum occurred earlier in monensin-fed cows than in the control group (27.2 +/- 2.1 d vs. 32.4 +/- 1.5 d), with no dietary effects on the diameter of the ovulating follicle. Similarly, treatments did not differ in the proportion of cows with 2 or 3 waves of ovarian follicular development per cycle, nor in the number of follicles of all classes during the breeding period. Times of ovulation following treatment with prostaglandin F2alpha were not different between dietary groups. Pregnancy rates after timed artificial insemination were similar between diets. Supplementation with monensin resulted in a shorter postpartum interval to first ovulation but did not affect other reproductive measures in healthy, lactating dairy cows.

Animal Feed↗
PubMed2003

Short communication: Effects of a monensin premix on milk fatty acid content during subacute ruminal acidosis in dairy cows.

The effects of a monensin premix on milk fatty acid content during grain-induced subacute ruminal acidosis (SARA) in Holstein cows receiving a total mixed ration was investigated. Six multiparous, rumen-fistulated Holstein cows were used in a two-treatment, two-period crossover design with 6-wk periods. Experimental treatments were either a monensin premix or a placebo premix. At the beginning of wk 4, SARA was induced in experimental cows for a 10-d period using a grain challenge model. The administration of a monensin premix elevated milk fat proportion of total short-chain saturated fatty acids (sum of C4 to C15). Milk fat proportions of conjugated linoleic acid isomers were unaffected. Linolenic acid (C18:3n3) proportion in milk fat of monensin-treated cows were lower when compared with placebo-treated cows during the SARA period. Results from this study indicate that dietary supplementation with monensin during SARA had little effect on milk fatty acid content.

Acidosis↗
PubMed2003

A field study of dietary interactions with monensin on milk fat percentage in lactating dairy cattle.

Ninety-one Ontario Holstein dairy herds were surveyed about their lactating cow ration and use of a premix containing monensin to identify possible dietary interactions with monensin on milk fat suppression. All herds were enrolled in Ontario Dairy Herd Improvement (DHI) milk recording, and results from four DHI tests were used. Herd mean fat tests were calculated only for cows between 100 and 200 d in milk to avoid potential confounding due to stage of lactation. Wet forage and total mixed ration (TMR) samples from all herds were evaluated for particle size using the Penn State Particle Size Separator. Of the herds using monensin (n = 58), the dose (per kg of dry matter) ranged from 9 to 14 mg/kg in TMR-fed herds and from approximately 9 to 23 mg/kg in herds in which concentrates were fed separately from forages (component-fed). Of the samples submitted for particle size evaluation, 15% of the haylage (n = 80), 14% of the corn silage (n = 79), and 42% of the TMR (n = 58) samples were classified as having low fiber. There was a significant negative univariable association between monensin and mean milk fat percentage. Monensin significantly reduced milk fat percentage in TMR-fed but not component-fed herds. Fiber length significantly interacted with monensin in TMR-fed herds: Herds that had low fiber in their TMR (< or = 6.0% in the top screen) were susceptible to milk fat decrease by monensin, whereas herds that had adequate fiber (> 6.0%) were not. Monensin also significantly reduced milk fat percentage in herds receiving diets low in nonstructural carbohydrate (< 40.2%) but not in those receiving diets high in NSC (> or = 40.2%). The results of this study suggest that there are significant interactions between monensin and certain dietary factors on milk fat suppression in Holstein dairy herds.

Animals↗
PubMed2002

Prepartum monensin for the reduction of energy associated disease in postpartum dairy cows.

A total of 1317 Holstein cows from 45 farms in the Canadian provinces of Quebec, Prince Edward Island (PEI) and Ontario were enrolled in a randomized trial during 1998 and 1999 to further confirm the efficacy of a monensin controlled release capsule in preventing periparturient disease in lactating dairy cows. Cows were randomized on the farms to receive either a monensin controlled release capsule (CRC) 2 to 4 wk before expected calving or to serve as negative controls. Health data were collected for 90 d postcalving and were analyzed with logistic regression accounting for the intraherd correlation with generalized estimating equations. Monensin CRC significantly reduced the incidence of both clinical ketosis and abomasal displacement post-calving. There was a numerical but nonsignificant decrease in the incidence of retained placenta in cows receiving a monensin CRC. A pooled analysis of two separate but similar studies (conducted in 1995 and 1998) demonstrated a strengthened association between monensin CRC administration precalving and reduced periparturient disease. A 40% reduction in both abomasal displacement and clinical ketosis was observed with precalving administration of a monensin CRC. In addition, the larger dataset highlighted a trend for a 25% reduction in the incidence of retained placenta in monensin-treated cows. Improved energy metabolism as a result of monensin treatment is likely the mechanism for the reduction in incidence of all three of these diseases. Thus the term "energy associated disease" was created to assess the combined impact of the precalving monensin treatment on the incidence of retained placenta, displaced abomasum, and clinical ketosis. The monensin controlled release capsule reduced the incidence of energy associated disease by 30%.

Abomasum↗
PubMed2002

The efficacy of intramammary tilmicosin at drying-off, and other risk factors for the prevention of new intramammary infections during the dry period.

The objective of this study was to compare the efficacy of an intramammary infusion, containing tilmicosin phosphate, to an infusion of a negative control intramammary placebo for preventing new intramammary infections (IMI) during the dry period. Cows were enrolled from 24 dairy herds from three geographical regions of Canada. Data from 248 cows and 938 bacteriologically negative quarters at drying-off are summarized. Overall, the rate of new IMI during the dry period was 16.7% of quarters. The new infection rates for quarters that received intramammary tilmicosin compared with the intramammary placebo were 14.4 and 19.4%, respectively. The majority of new IMI was caused by coagulase-negative staphylococci (49%) and environmental streptococcal organisms (26.8%). The probability for quarters to develop new IMI in the dry period was significantly increased when cows had higher milk production before drying-off (P = 0.04), when cows had longer dry periods (P = 0.02), and when dry cows were housed in tie-stall barns (P = 0.002). Higher parity cows and those that had a linear score somatic cell count (SCC) above 4 on the last DHI test were also at increased risk for new IMI (P < 0.10). Administration of intramammary tilmicosin appears to be an efficacious therapy for prevention of new IMI; however, there is currently no approved intramammary formulation of this product available. Use of blanket dry cow antibiotic therapy compared to selective dry cow therapy, as well as the importance of identifying risk factors and managing the environment of dry cows are discussed.

Animals↗
PubMed2002

Effects of a monensin controlled-release capsule or premix on attenuation of subacute ruminal acidosis in dairy cows.

The effects of monensin, administered either as a controlled release capsule (CRC) or a premix, on attenuating grain-induced subacute ruminal acidosis (SARA) and on ruminal fermentation characteristics in Holstein cows receiving a total mixed ration were investigated in two experiments. In both experiments, six multiparous, rumen-fistulated Holstein cows were used in a two-treatment, two-period crossover design with 6-wk periods. In Experiment 1, treatments were either a monensin CRC or a placebo CRC. In Experiment 2, treatments were either a monensin premix or a placebo premix. In both experiments, at the beginning of wk 4 SARA was induced in experimental cows for a 10-d period with a grain challenge model, and ruminal pH was measured continuously using indwelling pH probes. The administration of monensin either as a CRC or a premix had no effect on ruminal pH characteristics. Neither monensin CRC nor premix had an effect on ruminal volatile fatty acid concentrations, but reduced the acetate:propionate ratio. Monensin premix-treated cows were observed to have increased milk yield, largely as a result of a higher dry matter intake in monensin-treated cows compared to control cows. Milk fat content and yield were lower in monensin-treated cows compared to placebo-treated cows during SARA. In conclusion, there is no evidence that monensin was efficacious in raising ruminal pH during SARA under the conditions employed in this study.

Acidosis↗
PubMed2000

Tilmicosin induces apoptosis in bovine peripheral neutrophils in the presence or in the absence of Pasteurella haemolytica and promotes neutrophil phagocytosis by macrophages.

Pathogen virulence factors and inflammation are responsible for tissue injury associated with respiratory failure in bacterial pneumonia, as seen in the bovine lung infected with Pasteurella haemolytica. Tilmicosin is a macrolide antibiotic used for the treatment of bovine bacterial pneumonia. Recent evidence suggests that tilmicosin-induced neutrophil apoptosis may have anti-inflammatory effects. Using bovine leukocytes, we sought to define whether live P. haemolytica affected tilmicosin-induced neutrophil apoptosis, assessed the proapoptotic effects of tilmicosin in comparison with other drugs, and characterized its impact on phagocytic uptake of neutrophils by macrophages. Induction of apoptosis in the presence or absence of P. haemolytica was assessed by using an enzyme-linked immunosorbent assay for apoptotic nucleosomes. In addition, fluorescent annexin-V staining identified externalized phosphatidylserine in neutrophils treated with tilmicosin, penicillin, ceftiofur, oxytetracycline, or dexamethasone. Neutrophil membrane integrity was assessed by using propidium iodide and trypan blue exclusion. As phagocytic clearance of apoptotic neutrophils by macrophages contributes to the resolution of inflammation, phagocytosis of tilmicosin-treated neutrophils by esterase-positive cultured bovine macrophages was assessed with light microscopy and transmission electron microscopy. Unlike bovine neutrophils treated with penicillin, ceftiofur, oxytetracycline, or dexamethasone, neutrophils exposed to tilmicosin became apoptotic, regardless of the presence or absence of P. haemolytica. Tilmicosin-treated apoptotic neutrophils were phagocytosed at a significantly greater rate by bovine macrophages than were control neutrophils. In conclusion, tilmicosin-induced neutrophil apoptosis occurs regardless of the presence or absence of live P. haemolytica, exhibits at least some degree of drug specificity, and promotes phagocytic clearance of the dying inflammatory cells.

Animals↗
PubMed2000

Short communication: effects of monensin on 3-methylhistidine excretion in transition dairy cows.

Urinary 3 methyl-histidine excretion was measured in high yielding dairy cows between 10 and 3 d precalving and between 3 and 9 d postcalving. Cows received a sodium monensin controlled-release capsule or a placebo 3 wk before calving. Monensin did not affect urinary 3 methyl-histidine. Average urinary 3 methyl-histidine excretion was significantly higher postcalving (4.11 mmol d(-1)) than precalving (2.48 mmol d(-1)). This increase is assumed to be predominantly due to the negative nitrogen balance in the postcalving period caused by insufficient nutrient intake to meet nutrient requirements, which necessitates catabolism of mainly myofibrillar protein.

Animals↗
PubMed2000

Effect of a prepartum administration of monensin in a controlled-release capsule on apparent digestibilities and nitrogen utilization in transition dairy cows.

The influence of a monensin controlled-release capsule, which was administered 3 wk before the calving date, on diet digestibility and nitrogen utilization was investigated in 16 multiparous dairy cows between approximately 10 and 3 d precalving and 3 and 9 d postcalving. Monensin decreased rumen ammonia from 5.4 to 3.2 mg dl(-1) precalving and from 6.0 to 4.9 mg dl(-1) postcalving. Blood urea concentrations were increased by monensin from 4.93 to 5.28 mM precalving and from 5.27 to 5.81 mM postcalving, but these increases were not statistically significant. Precalving, monensin increased the apparent digestibilities of neutral detergent fiber from 52.8 to 62.1%, of acid detergent fiber from 50.7 to 58.7%, and of gross energy from 60.5 to 66.7%. Postcalving, monensin increased the apparent nitrogen digestibility from 63.7 to 71.5%, which resulted in an improvement in the nitrogen balance from -77.8 to -44.9 g d(-1). The monensin controlled-release capsule contributed to increasing the availability of dietary nitrogen to the transition dairy cow during the critical postcalving period.

Ammonia↗
PubMed2000

The effect of tilmicosin administered to ewes prior to lambing on incidence of clinical mastitis and subsequent lamb performance.

The effect of tilmicosin on the incidence of clinical mastitis and subsequent lamb performance was studied in 9 sheep flocks in Ontario. Ewes were treated randomly with either tilmicosin or placebo approximately one month prior to lambing. Outcome was assessed by comparing rates of clinical mastitis, palpable udder abnormalities, and preweaning (50-day) lamb weights between the 2 treatment groups, while controlling for other important variables. Lambs raised by multiparous ewes treated with tilmicosin were significantly heavier than lambs from placebo-treated multiparous ewes at 50 days. Lambs from tilmicosin-treated ewes were on average 0.52 kg heavier than lambs in the placebo group. There was no difference between treatment groups in the weight of lambs from first parity ewes. Tilmicosin treatment resulted in a 43% decrease in palpable udder abnormalities. Incidence of clinical mastitis did not differ between experimental groups. The administration of tilmicosin prelambing, at the time of routine clostridial disease vaccination, may be a beneficial and convenient way to reduce mastitis infection and improve the preweaning gain of lambs.

Animals↗